SAPX, SHMX, SEED, SMNG, MHYS, NGEN
Our Stocks to Watch today include Biostem U.S. Corp. (OTC: HAIR), Seven Arts Entertainment Inc. (Nasdaq: SAPX), Shamika 2 Gold Inc. (OTCBB: SHMX), Origin Agritech Ltd. (Nasdaq: SEED), Strategic Mining Corp. (OTCBB: SMNG), Mass Hysteria Entertainment Co. (OTC: MHYS) and Nanogen Inc. (OTC: NGEN).
BIOSTEM U.S. CORPORATION (OTC: HAIR)
Detailed Quote: http://www.otcpicks.com/quotes/HAIR.php
Company Profile: http://www.biostem.us
Biostem U.S., Corporation (HAIR) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem U.S. is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.
August 7 - Biostem U.S., Corporation Appoints Marina Pizarro, M.D. to Scientific and Medical Board of Advisors (SAMBA)
Hair Transplant Physician Joins Prestigious Group of Physicians With Interests in the Advancement of Stem Cell Technologies in Wide Range of Disciplines
Biostem U.S., Corporation (OTC: HAIR) (“Biostem” or “the Company”), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced the appointment of Marina Pizarro, M.D. to its Scientific and Medical Board of Advisors (SAMBA). Chief Executive Officer Dwight Brunoehler stated, "The addition of Dr. Pizarro to Scientific and Medical Board of Advisors rounds out our team with expertise in the field of hair re-growth using stem cells. We look forward to her interaction with the members to help advance the Company's mission to improve the quality and longevity of life for all mankind through the use of ethically sourced stem cells."
Dr. Pizarro is currently the Medical Director for Biostem U.S. as well as their trainer for the Company's hair re-growth Affiliate Program. As the company accepts qualified affiliate physicians to administer The Biostem Method™ of hair re-growth throughout the United States, Dr. Pizarro will oversee their training at her Orlando, Florida location, where she is currently accepting patients. Dr. Pizarro will begin offering the Biostem Method™ in her Tampa and Jacksonville, Florida offices in the coming months. She will also assist in overseeing the set-up of another training facility overseas as the company expands its Medical Affiliate Program internationally.
Dr. Marina Pizarro holds the distinction of being the first female hair transplant physician in the industry and belongs to the elite group of surgeons who have performed over 30,000 hair transplant procedures in their careers. She received her medical degree from Ponce School of Medicine in Puerto Rico in 1985. After completing her residency in Orlando, Dr. Pizarro worked with world renowned hair transplant surgeon Dr. Constantine Chambers building one of the largest hair restoration practices in history. After five years, and after having performed thousands of procedures around the world while lecturing at hair restoration conventions, Dr. Pizarro opened her first two facilities in Orlando and Jacksonville, Florida in 1994, specializing in hair transplantation for both men and women. She currently has three facilities in Florida with the addition of her clinic in Tampa. Dr. Pizarro is a member of The International Society of Hair Restoration Surgery and the European Society of Hair Restoration Surgery.
SEVEN ARTS ENTERTAINMENT INCORPORATED (NASDAQ: SAPX)
"Up 33.60% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SAPX.php
Seven Arts Entertainment Inc. is the successor to Seven Arts Pictures Plc., which was founded in 2002 as an independent motion picture production and distribution company engaged in the development, acquisition, financing, production, and licensing of theatrical motion pictures for exhibition in domestic (i.e., the United States and Canada) and foreign theatrical markets, and for subsequent worldwide release in other forms of media, including home video and pay and free television.
August 7 - Seven Arts Entertainment Announces a Stock Repurchase Program
Seven Arts Entertainment Inc. (Nasdaq: SAPX) ("Seven Arts" or the "Company") announced today that its Board of Directors has authorized the adoption of a Stock Repurchase Program, pursuant to which the Company may repurchase up to $250,000 of its currently outstanding common stock at prevailing market prices up to $.10, as adjusted for any stock split. The time period during which the repurchasing activities may occur will be dependent on future market volume, but is expected to start immediately and continue through October 31, 2012. The Stock Repurchase Program is subject to various trading restrictions as established in Rule 10(b)-18 of the Securities Exchange Act of 1934.
CEO Peter Hoffman stated: "Management is aware of concerns of shareholders regarding the heavy selling of Seven Arts common stock and the potential effects on that selling of Seven Arts' previously announced program of converting its debt into equity. Management believes that this selling volume is far in excess of the number of new shares issued in debt conversion and that much selling pressure is the result of market strategies or manipulation, including substantial short selling as reflected in the failure to deliver chart. In response to those concerns, management has set aside and intends to further set aside from Seven Arts' expected tax credit collections up to $250,000 to provide bid support of our common stock up to $.10. Management continues to believe that those market participants 'betting against' Seven Arts will be disproven by financial results, which is the only viable long term strategy to defend against widespread manipulation and short term trading activities, and we believe such results will be forthcoming."
Management believes that the Seven Arts' debt conversion program has substantially strengthened the Company and prepared it for future growth. Seven Arts' shareholders equity is now estimated to be in excess of $25 million.
SHAMIKA 2 GOLD INCORPORATED (OTCBB: SHMX)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SHMX.php
Shamika 2 Gold, Inc. engages in acquiring and exploring gold and mineral properties located in Cambodia and Canada. It holds its interests in Samplout project that comprises an area of approximately 140 square miles in the Samplout/Samlaut area of Western Cambodia; and Montclerg property, which consists of 23 mineral claims covering an area of 17.5 square kilometers located approximately 200 kilometres east of Montreal. The company is based in New York, New York. Shamika 2 Gold, Inc. is a subsidiary of Shamika Resources Inc.
July 11 - Shamika 2 Gold, Inc. Letter to Shareholders
The following is a letter from Henry Riedl in regards to a general update of the business:
As many of you know, Shamika 2 Gold, Inc. (OTCBB: SHMX) reconstituted its management team on March 20, 2012. I have taken over the roles of President, CEO and Interim CFO. Kim Koffel, previously a member of the Board, also assumed the role as Chief Operating Officer for which the Company is pleased to take advantage of his considerable expertise. In addition, the Company's other Board members and executive officers resigned as of that date. Terence Ortslan was also re-appointed to the Board and we welcome his considerable mining expertise.
Since that time, management has spent considerable time and effort in maintaining the Company's required filings and updating its website.
Previous management has been replaced and are no longer involved in the affairs of the Company. As a result, overhead expenses have been reduced to a strict minimum and will remain at this level for the foreseeable future. We are in the process of rebuilding the management team.
We are actively reviewing and evaluating mining properties that have a medium term possibility of generating cash flow. We have finalized two rounds of financing with an investor that have permitted the Company to remain current in its SEC and State of Nevada filings.
We have reactivated the website. However, we are in the process of revising its content so that it fully represents the activities of the Company.
ORIGIN AGRITECH LIMITED (NASDAQ: SEED)
"Up 13.77% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SEED.php
Founded in 1997 and headquartered in Beijing, Origin Agritech Limited is China’s leading, vertically-integrated agricultural biotechnology company specializing in research, development and production to supply the growing populations of China. Origin develops, grows, processes, and markets high quality, hybrid crop seeds to farmers throughout China and parts of Southeast Asia via a network of approximately 3,800 first-level distributors and 65,000 second-level distributors and retailers, and possesses a pipeline of genetically modified seed products including glyphosate resistant corn and Bt Corn. The first genetically modified corn seed product for China, Phytase corn, was approved in November 2009 of which Origin possesses exclusive rights.
August 7 - Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
* Revenues increased by 10% year-over-year from RMB244.7 million to RMB269.3 million
* Net income attributable to Origin Agritech was RMB25.4 million, EPS of RMB1.09
Origin Agritech Limited (Nasdaq: SEED) ("Origin" or the "Company") , a technology-focused supplier of hybrid and genetically modified crop seeds in China, today announced unaudited financial results for the third quarter ended June 30, 2012. Origin prepares its financial statements in accordance with generally accepted accounting principles (GAAP) of the United States.
FINANCIAL RESULTS OVERVIEW
During the third quarter of fiscal 2012, revenues increased by 10.1% year-over-year to RMB269.3 million (US$42.7 million) from RMB244.7 million one year ago. Higher revenues this quarter were mainly due to earlier sales settlement with the distributors for the 2012 selling season.
Deferred revenues were RMB257.3 million (US$40.7 million) as of June 30, 2012 compared with RMB287.2 million on June 30, 2011. Deferred revenues mainly reflect the value of Origin's crop seeds after a) sales arrangement is confirmed; b) delivery to the customer is made; and c) pre-payment from the customer is received, but before the final sales price is fixed and determined. The final sales price is primarily determined by sales incentives that Origin gives to its customers. The year-over-year decrease in deferred revenues was mainly due to more revenue is recognized in the current period of this year. Deferred revenues as of June 30, 2012 also included a total of RMB24.9 million (US$3.9 million) of subsidies received from various levels of the Chinese government.
The sum of recognized revenues for the first nine months ended June 30, 2012 and deferred revenues as of June 30, 2012 were RMB568.3 million (US$90.0 million), compared with RMB550.1 million for the same period last year. Excluding the deferred government subsidies, Changchun Origin and the divestiture of Jilin Changrong, the sum of revenues for the first nine months ended June 30, 2012 and deferred revenues as of June 30, 2012 increased by 20.6% year-over-year to RMB493.4 million (US$78.2 million) from RMB409.1 million as of June 30, 2011. This year-over-year increase in recognized and deferred revenues was mainly due to an increase in corn seed shipping volume during the 2012 planting season. The table below lists the deferred revenues and recognized revenues with and without the contribution from Jilin Changrong and Changchun Origin, and government subsidies.
Notes: After the divestiture of Jilin Changrong Hi-tech Seed Company Limited ("Jilin Changrong") in fiscal year 2011, Changchun Origin Seed Technology Development Limited ("Changchun Origin") started operation in the same Northeastern region in fiscal year 2012.
Gross profit for the third quarter of fiscal 2012 was RMB54.2 million (US$8.6 million) compared to RMB85.8 million in the third quarter of fiscal 2011.
Total net operating expenses for the three months ended June 30, 2012 decreased to RMB30.2 million (US$4.8 million) from RMB51.9 million during the same period in fiscal 2011. Lower operating expenses during the third quarter of fiscal 2012 were mainly due to a decrease in costs previously associated with Jilin Changrong, which are no longer applicable after the divestiture. Specifically, selling and marketing expenses were RMB10.3 million (US$1.6 million) for the third quarter of fiscal 2012, compared with RMB12.6 million for the same period last year. General and administrative ("G&A") expenses decreased by 45.9% year-over-year to RMB12.9 million (US$2.0 million) from RMB23.8 million for the third quarter of fiscal 2011. Research and development ("R&D") expenses were RMB8.2 million (US$1.3 million) for the three months ended June 30, 2012, compared with RMB15.5 million during the same period last year.
Income from operations for the third quarter of fiscal 2012 amounted to RMB24.1 million (US$3.8 million) compared with income from operations of RMB33.9 million for the same period in fiscal 2011.
Net income attributable to Origin for the third quarter of fiscal 2012 was RMB25.4 million (US$4.0 million), or RMB1.09 (US$0.17) per share - both basic and diluted, compared with a net income of RMB13.9 million, or RMB0.60 per share - both basic and diluted during the same period one year ago.
As of June 30, 2012, cash and cash equivalents were RMB194.2 million (US$30.7 million), and shareholders' equity was RMB217.4 million (US$34.4 million). Short-term borrowings were RMB39.0 million (US$6.2 million). Long-term borrowings were RMB30.0 million (US$4.7 million), representing bank borrowings to finance the construction of the seed conditioning plant in Xinjiang.
Advances from customers were RMB365.8 million (US$57.8 million) as of June 30, 2012 compared with RMB290.8 million a year ago. These advances represent cash receipts for future orders.
STRATEGIC MINING CORPORATION (OTC: SMNG)
"Up 20.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SMNG.php
Strategic Mining Corp.'s goal is to become a significant explorer and developer of gold properties in Guinea and Vietnam. It is currently planning more exploration and development programs on its Siguiri property, and intends to expand its property base in Guinea by acquisition and joint venture
No recent news for Strategic Mining Corp. (OTCBB: SMNG).
MASS HYSTERIA ENTERTAINMENT COMPANY (OTC: MHYS)
"Up 28.57% in morning trading"
Detailed Quote: www.otcpicks.com/quotes/MHYS.php
Mass Hysteria Entertainment, Inc. Is a development stage multi-media entertainment company created to produce theatrical films with an interactive component. Mass Hysteria is the next step in the evolution of the theatrical experience: a hybrid entertainment that combines movies with hand-held devices and the internet.
July 24 - Mass Hysteria Entertainment Company CEO Daniel Grodnik To Be Interviewed On StockTradersTalk Radio
Mass Hysteria Entertainment Company, Inc. (OTC: MHYS) announced today that its Chief Executive Officer, Daniel Grodnik, will be the featured guest in an exclusive interview on StockTradersTalk Radio tomorrow night at 8pm EST. Mr. Grodnik is expected to discuss Mass Hysteria's business and strategy for the future.
"I am pleased to have this opportunity to discuss what our company is doing and our plans for the future," stated Daniel Grodnik, Mass Hysteria's CEO. "We are making strides and I am looking forward to sharing some of our progress with the investment community."
The interview will be held on July 25th, 2012 at 8:00 pm EDT. Listeners can access the live sessions by visiting www.blogtalkradio.com/stocktraderstalk. An archived recorded version will be located on the homepage of Stock Traders at www.stocktraderstalk.com, following the interview.
NANOGEN INCORPORATED (OTC: NGEN)
"Up 87.50% in morning trading"
Detailed Quote: www.otcpicks.com/quotes/NGEN.php
Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe. It offers diagnostic test kits and reagents based on polymerase chain reaction (PCR) technology in the molecular diagnostic market. The company’s PCR molecular product lines comprise Q-PCR Alert products for in-vitro diagnostic use, and are sold in Italy via a contract sales force and in other European countries through a network of distributors; and MGB Alert products. It also offers point-of-care products, which include qualitative cardiac test products that are rapid test assays used in emergency care settings for the diagnosis of myocardial infarction; quantitative cardiac tests, a quantitative test measuring the concentration of the peptide NT-proBNP for the diagnosis of congestive heart failure; and pandemic influenza test that detects and differentiates the various strains of influenza, including potential pandemic strains. The company was founded in 1993 and is headquartered in San Diego, California.
No recent news for Nanogen, Inc. (OTC: NGEN).